[1] Brandao R,Marcelino R,Goncalves F,et al.Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a portuguese cohort.Viruses,2018,10:E223.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版).中华传染病杂志,2015,33:705-724.
[3] Schnell G,Krishnan P,Tripathi R,et al.Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.PLoS One,2018,13:e0205186.
[4] Kohler JJ,Nettles JH,Amblard F,et al.Approaches to hepatitis C treatment and cure using NS5A inhibitors.Infect Drug Resist,2014,7:41-56.
[5] Sarrazin C,Zeuzem S.Resistance to direct antiviral agents in patients with hepatitis C virus infection.Gastroenterology,2010,138:447-462.
[6] Nakamoto S,Kanda T,Wu S,et al.Hepatitis C virus NS5A inhibitors and drug resistance mutations.World J Gastroenterol,2014,20:2902-2912.
[7] Wei L,Wang FS,Zhang MX,et al.Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.World J Gastroenterol,2018, 24:1361-1372. |
